2021 Fiscal Year Final Research Report
Establishment of a novel therapy for hemiplegia through repair pathways of Reelin/Disabled/GSK3.
| Project/Area Number |
18K09009
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 56010:Neurosurgery-related
|
|---|
| Research Institution | St. Marianna University School of Medicine |
|---|
Principal Investigator |
Takai Kenji 聖マリアンナ医科大学, 医学部, 教授 (60121167)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
鈴木 登 聖マリアンナ医科大学, 医学部, 教授 (40235982)
|
|---|
| Project Period (FY) |
2018-04-01 – 2022-03-31
|
| Keywords | 大脳皮質運動野損傷 / 片麻痺 / 細胞移植治療 / ニューロスフェア / Reelin / Disabled1 / yotariマウス / 神経再生 |
|---|
| Outline of Final Research Achievements |
Although the number of patients with cerebrovascular disease in Japan has been decreasing in recent years, it has exceeded 1 million, and 20,000 new cases are seen every year. It requires rehabilitation and long-term care, which is a burden on the person and society, and the current treatment method: suppression of acute neurodegeneration does not change. Therefore, we conducted a mouse transplantation experiment to see if radical treatment could be performed by transplanting neural stem/progenitor cells (NSPCs) derived from human iPS cells or mouse neurosphere constituent cells. The motor area of the cerebral cortex was experimentally damaged to cause hemiplegia, and when NSPCs were transplanted into the striatum below the injured area, motor function was restored. To explore this mechanism, we focused on Reelin, which plays an important role in the developmental stage of the cerebral cortex, and confirmed that it is also involved in nerve regeneration in adult mice.
|
| Free Research Field |
再生医学
|
| Academic Significance and Societal Importance of the Research Achievements |
脳血管疾患に対して、ヒトiPS細胞由来あるいはマウスニューロスフェア細胞などの神経前駆細胞（NSPCs）の移植によって根治的治療を行えないか、マウスの移植実験を行った。疾患モデルは、マウスの大脳皮質運動野の凍結損傷とし、移植細胞としてはヒトiPS細胞、あるいはマウスニューロスフェアを用いた。iPS細胞を用いることは、ES細胞を用いることに対する免疫学的・倫理的問題や細胞ソースの問題をクリアできる。マウスニューロスフェア細胞については、移植細胞とした場合、回復過程の起点と考えられるDab1遺伝子knockoutマウスに相当するyot/yotマウスを用いて、これと比較が出来るという理由による。
|
